Business

Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®

Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®.

articleEndonovo Therapeutics, Inc.July 27, 20205/company/endonovo-therapeutics-inc/news/endonovo-therapeutics-announces-significant-results-from-study-showing-70percent-reduction-of-morphine-equivalent-dose-and-2-day-reduction-of-length-of-stay-at-hospitals-using-sofpulser
Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®

About this update from Endonovo Therapeutics, Inc.

[{"type":"text","content":"\n LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), today announced that an investigator initiated study, authored by Dr. Samir Awad, Professor of Surgery at Baylor College of Medicine, entitled ‘The Impact of Pulsed Electromagnetic Field (SofPulse®) on Postoperative Pain in Patients Undergoing Cardiothoracic Surgery’ was accepted for oral presentation at the 44th Annual meeting of the Association of VA Surgeons. The study was conducted on 31 patients from 1/1/2019 thru 12/31/2019 with sixteen patients using SofPulse® adjunctively for recovery and fifteen patients not using SofPulse®. Both groups of patients were well matched with no significant difference in: Age, BMI, Gender, Comorbidities, ETOH, Tobacco, and history of opioid use. The results of the study demonstrate that the use of SofPulse® significantly decreased postoperative pain VAS (Visual Analog Scale) by 50%, decreased postoperative opioid requirements (morphine equivalent dose) by 70%, and resulted in a significant decrease in Length of Stay at the hospital by a median of 2 days. Endonovo CEO Alan Collier stated, “The economic findings, cost savings, and reduction of opioid use to hospitals and patients recovering from open heart types of surgeries from the Baylor College of Medicine study are stunning. Findings show a significant reduction in the median Length of Stay (LOS) of 2 days for open heart type of surgeries, we believe this makes SofPulse® a viable option for reducing length of stay on any inpatient or outpatient surgical procedure done in the US. Using SofPulse® for postoperative pain and edema reduction basically offers hospitals a cost savings from a reduction of the length of stay by 2 days for patients to recover from these types of surgeries. With hospital costs constantly going up and with a current per daily average of $3000 to $6000 for surgical recovery stays, this reduction in length of stay could equate to a $6,000 to $12,000 savings to hospitals, per patient, when using SofPulse® for these types of surgeries.” Collier continues, “We are thrilled to announce that Dr. Awad will be presenting his research findings to his colleagues, the medical community and anyone in the public who would be interested. This ...

More updates from Endonovo Therapeutics, Inc.